Loss of epithelial membrane protein-2 expression confers an independent prognosticator in gallbladder carcinoma  by Li, Chien-Feng et al.
Biomarkers and Genomic Medicine (2013) 5, 31e38Available online at www.sciencedirect.com
journal homepage: www.j -bgm.comORIGINAL ARTICLE
Loss of epithelial membrane protein-2 expression
confers an independent prognosticator in gallbladder
carcinomaChien-Feng Li a,b,c,d, Li-Tzong Chen c,e,f, Ching-Yih Lin g,h, Yu-Hui Wang i,
Hsuan-Ying Huang j, Chung-Hsi Hsing k, Chia-Jung Tsai l, Yow-Ling Shiue l,m,*aDepartment of Pathology, Chi-Mei Foundation Medical Center, Tainan, Taiwan
bGraduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
cNational Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan
dDepartment of Biotechnology, Southern Taiwan University of Science and Technology, Tainan, Taiwan
eDepartment of Internal Medicine and Cancer Center, National Cheng Kung University Hospital, Tainan, Taiwan
f Institute of Molecular Medicine, National Cheng Kung University, Tainan, Taiwan
gDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Chi-Mei Foundation Medical Center,
Tainan, Taiwan
hDepartment of Leisure, Recreation, and Tourism Management, Southern Taiwan University of Science and Technology,
Tainan, Taiwan
iBiosignal Transduction, National Cheng Kung University, Tainan, Taiwan
jDepartment of Pathology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University, College of Medicine,
Kaohsiung, Taiwan
kDepartment of Anesthesiology, Chi-Mei Foundation Medical Center, Tainan, Taiwan
l Institute of Biomedical Science, National Sun Yat-sen University, Kaohsiung, Taiwan
mDepartment of Biological Sciences, National Sun Yat-sen University, Kaohsiung, Taiwan
Received 8 March 2013; received in revised form 9 April 2013; accepted 10 April 2013
Available online 15 May 2013KEYWORDS
epithelial membrane
protein-2;
gallbladder
carcinoma;
survival* Corresponding author. Institute of
E-mail address: ylshiue@mail.nsysu
2211-4254/$36 Copyright ª 2013, Taiw
http://dx.doi.org/10.1016/j.gmbhs.20Abstract The objective of this study was to evaluate the expression of epithelial membrane
protein-2 (EMP2) and its clinicopathological associations in patients with gallbladder carcinoma
(GBC). A retrospective population-based cohort study was performed based on a biobank from
1986 to 2005. Biopsies of 164 GBC patients without initial distant metastasis were collected
during surgical intervention. Immunoexpressions of EMP2 and Ki-67 were analyzed and the out-
comes were correlated with clinicopathological features and patient survival. Results indi-
cated that loss of EMP2 expression (50%) was correlated with female patients (p Z 0.037),
advanced primary tumor (p < 0.017), vascular (p < 0.001), and perineural (p < 0.027) invasionsBiomedical Science, National Sun Yat-sen University, 70 Lienhai Rd., 80424 Kaohsiung, Taiwan.
.edu.tw (Y.-L. Shiue).
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32 C.-F. Li et al.and high Ki-67 labeling index (p < 0.001).In multivariate analysis, loss of EMP2 expression, high
Ki-67 labeling index, and age emerged as independent prognosticators for worse disease-
specific (p < 0.001; p < 0.001; and p Z 0.001, respectively) and disease-free (p Z 0.002;
pZ 0.002; and pZ 0.008, respectively) survivals, following by the American Joint Committee
on Cancer stage (p < 0.001; p < 0.001; and p < 0.001, respectively). Collectively, loss of EMP2
expression is common and associated with adverse prognosticators and might confer tumor
aggressiveness through hampering its interaction with specific membrane protein(s) and anti-
proliferative activity, and perhaps the downstream signal transduction pathway(s).
Copyright ª 2013, Taiwan Genomic Medicine and Biomarker Society. Published by Elsevier
Taiwan LLC. All rights reserved.Table 1 Clinicopathological features of 164 gallbladder
adenocarcinomas.
Parameter Patient (n) %
Gender
Male 63 38.4
Female 101 61.6
Age (y)
60 38 23.2
61e70 55 33.5
71e80 50 30.5
81e90 18 11.0
90 3 1.8
Primary tumor (pT)
T1 33 20.1
T2 55 33.5
T3 74 45.1
T4 2 1.2
Stage
I 30 18.3
II 44 26.8
III 78 47.6
IV 12 7.3
Histological type
Tubular 135 82.3
Papillary 17 10.4
Others Adenosquamous (5), 7.3
Undifferentiated (4),
Signet-ring (2),
Clear cell (1)
Histological grade
1 65 39.6
2 69 42.1
3 26 15.9
4 4 2.4
Vascular invasion
Present 106 64.6
Absent 58 35.4
Perineural invasion
Present 140 85.4
Absent 24 14.6
Tumor necrosis
Present 87 53.0
Absent 77 47.0Introduction
Gallbladder carcinoma (GBC) is a rare malignant tumor and
its etiology is poorly understood. The prevalence is variable
globally, with higher occurrence in Asia, Latin America, and
Eastern Europe.1 Potential risk factors include age, gender,
chronic inflammation, gallstones, infection, chemical pol-
lutants, and gallbladder polyps.2,3 Tumor, node, and
metastasis stage remain the best prognosticators for GBC at
present. Surgical intervention is the only curative treatment
option. An R0 resection (complete removal with microscopic
examination of margins with no residual tumor) in subse-
quent re-exploration gives a better patient outcome. The
median survival was 72months for patient with GBC removed
by simple cholecystectomy; however, this is significantly
reduced to 12.7 months when microscopic or macroscopic
residual disease was found after re-exploration.4 The role of
systemic treatment in GBC is still unclear, although a few
retrospective or small Phase II studies show that GBC pa-
tients may benefit from adjuvant therapy.5 Despite the
improvement of the treatment modality, the prognosis of
GBC remains dismal. The 5-year survival rate for GBC of each
stage is about 5%.6 Therefore, understanding the clinical and
molecular mechanisms of GBC will provide a cornerstone in
the development of early intervention, potential screening,
and, above all, more effective treatment strategies.3
Human epithelial membrane protein-2 gene (EMP2),
mapped to chromosome 16, is highly conserved across
vertebrates.7e9 The expression pattern of EMP2 partially
overlaps that of the peripheral myelin protein 22 transcript
[PMP22, also known as the growth arrest-specific-3 (GAS3)].
By containing the claudin domain and sharing approxi-
mately 40% amino acid identity with PMP22/GAS3,10 the
EMP2 protein was detected as a novel member of this four-
transmembrane (tetraspan) superfamily.11 In humans, EMP2
has a discrete cell type and tissue distribution, with high
levels observed in the lung and moderate levels in the eye,
heart, thyroid, uterus, and intestine.10,12,13 Functionally,
the best understood tetraspan proteins are connexins,
which form the major structural element of gap junctions.
Connexins play important roles in the regulation of cell
growth and differentiation. Cancer cells usually have
downregulated levels of gap junctions, and several lines of
evidence suggest that loss of gap junctional intercellular
communication is an important step in carcinogenesis.
Re-expression of connexins in cancer cells causes normali-
zation of cell growth control and reduced tumor growth.14
EMP2 expression in gallbladder cancer 33In this study, we aimed to analyze systematically EMP2
immunoexpression in patients with GBC and therefore
identify that loss of EMP2 expression is associated with
adverse prognosticators, conferring to poor survivals.
Materials and methods
Patients and tumor specimens
The institutional review board approved use of formalin-
fixed tissue of GBC for this study (IRB10203-003). A total of
164 patients who consecutively underwent surgery with
curative intent and free surgical margin (R0) between 1986
and 2005, were selected from the archives of Chi-Mei
Medical Center, Chang Gung Memorial Hospital, and Chan-
ghua Christian Hospital. The clinical information and the
pathological slides of the removed tumors were reviewed.
Of these patients, 104 received cholecystectomy and 60
received extend operation. The former procedure included
simple cholecystectomy or cholecystectomy with resection
of a 2 cm depth of the liver bed, and the latter operation
included a resection of adjacent organs in addition to the
gallbladder. Tumors removed from these patients were
categorized according to the latest World Health Organi-
zation classification and were staged by 7th edition Amer-
ican Joint Committee on Cancer (AJCC) system.15 Follow-up
data were available in 161 patients, with a median period
of 13 months (range, 1e234), for all patients. Of 72 survi-
vors, the median duration of follow-up was 19 months.
Immunohistochemical staining and assessment
Tissue section of 3 mm thickness were cut onto precoated
slides from paraffin-embedded tissue blocks and were next
routinely deparaffinized with xylene and rehydrated withFigure 1 Immunohistochemistry demonstrates that epithelial
epithelium; (B) variable in adenoma; (C) gradually decreases during
(right, upper); (D) strongly positive in well-differentiated, low-stag
high-stage adenocarcinoma; and (F) negative in poorly-differentiatethanol washes. Slides were heated bymicrowave in a 10mM
citrate buffer (pH 6.0) for 7 minutes to retrieve antigens.
Endogenous peroxidase was blocked with 3% H2O2. Slides
were next washed by Tris-buffered saline for 15 minutes and
subsequently incubated with a rabbit polyclonal primary
antibody targeting EMP2 (Atlas Antibodies, Stockholm,
Sweden) and Ki-67 (MIB-1; DAKO, Glostrup, Denmark) at di-
lutions of 1:75 and 1:100 for 1 hour, respectively. Primary
antibodies were detected using the ChemMate EnVision
Detection Kit (K5007; DAKO, Carpinteria, CA, USA). The
slides were incubated and developed with the secondary
antibody for 30 minutes and 3,3-diaminobenzidine for 5 mi-
nutes, followed by counterstained using Gill’s hematoxylin.
Incubation without the primary antibodywas used a negative
control. Immunoexpressions of EMP2 and Ki-67 were scored
by two pathologists (Li C.F. and Huang H.Y.) using a multi-
headed microscope to reach a consensus for each case
without prior knowledge of clinical and follow-up informa-
tion. Once 50% of tumor nuclei stained with Ki-67, was
designated as high labeling index. Scoring of EMP2 immuno-
reactivity was evaluated based on a combination of both the
percentage and intensity of positively stained tumoral
membrane and cytoplasm to generate the H-score, which
was calculated using the equation: H-score Z SPi(iþ1),
where iwas the intensity of stained tumor cells (0 to 4þ), and
Pi was the percentage of stained tumor cells for each in-
tensity varying from 0e100%. Tumors with H-score<median
of all cases were regarded as EMP2 low expression.Statistical analysis and follow-up
Statistics were performed using SPSS version 14.0 software
(SPSS Inc., Chicago, IL, USA). Chi-square test and Wilcoxon
test were used to compare the EMP2 expression level and
Ki-67 labeling index, respectively, with various clinicmembrane protein-2 expression is (A) negative in nontumor
transformation from adenoma (left, lower) to adenocarcinoma
e adenocarcinomas; (E) weakly positive in well-differentiated,
ed, high-stage adenocarcinoma.
34 C.-F. Li et al.opathological parameters. The end points analyzed were
disease-specific survival (DSS) and disease-free survivals
(DFS), calculated from the date of GBC surgical operation
to the presence of disease-related mortality and tumor
recurrence or systemic metastasis developed, respectively,
or at the last follow-up appointment. The KaplaneMeier
method and log-rank test were used to perform the uni-
variate survival analyses and to evaluate the prognostic
differences between groups. Parameters with p < 0.05 in
univariate analysis were subsequently included into the
multivariate assay with the Cox proportional hazard model.
For all analyses, two-sided tests of significance were used
with p < 0.05 considered significant.
Results
Clinicopathological features
The clinicopathological characters of GBC patients in this
study are listed in Table 1. Most patients were female and
aged >60 years. Around 80% of the patients with tumors
extend beyond muscle layer (T2 or above) during diagnosis.Table 2 Associations of EMP2 expression and clinicopathologica
Parametera Patient (n)
High
Gender
Male 63 38
Female 101 44
Age (y)
<70 86 42
70 78 40
Primary tumor (pT)
T1 33 21
T2 55 32
T3eT4 76 29
Stage
I 30 19
II 44 25
IIIeIV 90 38
Histological type
Papillary 17 11
Tubular 135 66
Others 12 5
Histological grade
Grade 1 80 45
Grade 2e4 84 37
Vascular invasion
Absent 106 69
Present 58 13
Perineural invasion
Absent 140 75
Present 24 7
Tumor necrosis
Absent 87 47
Present 77 35
Ki-67 labeling index 164 39.1
* Statistically significant.
a Apart from Ki-67 labeling index, all parameters were analyzed byHistologically, 135 tumors exhibit tubular arrangement and
17 tumors display papillary growth pattern. Other histo-
logical subtypes were also identified with low percentages,
including adenosquamous (n Z 5; 3%), undifferentiated
(n Z 4; 2.4%), signet-ring cell (n Z 2; 1.2%), and clear cell
(n Z1; 0.6%) carcinomas. The histological grading of the
tumors included 65 Grade 1, 69 Grade 2, 26 Grade 3, and
four Grade 4 tumors. Vascular and perineuralinvasions were
observed in 106 cases and 140 cases, respectively. Tumor
necrosis was seen in 87 events.
Correlations of EMP2 immunoexpression with
clinicopathologic variables and proliferative index
As shown in Fig. 1, EMP2 protein expression was identified in
both cytoplasm and membrane. In gall bladder tissues, EMP2
proteins were not expressed in the nontumor epithelium
(Fig. 1A), but were inconsistently but positively expressed in
the adenoma. During transformation from adenoma (left,
bottom; Fig. 1C) to adenocarcinoma (right, upper; Fig. 1C),
the EMP2 protein level gradually decreases. Intriguingly,
prominent EMP2 cytoplasmic and membrane expressionsl factors in 164 gallbladder carcinomas.
EMP2 immunoexpression p
Low
25 0.037*
57
44 0.754
38
12 0.017*
23
47
11 0.077
19
52
6 0.392
69
7
35 0.118
47
37 <0.001*
45
65 0.027*
17
40 0.273
42
 23.67 45.2  23.20 <0.001*
the Chi-square test.
EMP2 expression in gallbladder cancer 35were observed in well-differentiated, low-stage adenocarci-
nomas (Fig. 1D). Inwell-differentiated/high-stage and poorly-
differentiated/high-stage adenocarcinomas, EMP2 are
weakly and not expressed, respectively. After dichotomizing
the tumors into EMP2 high and low expressions, as demon-
strated in Table 2, low EMP2 protein levels correlated with
gender (p< 0.037), advanced primary tumor (pT; p< 0.017),
absence of vascular (p < 0.001) and perineural (p < 0.027)
invasions, and high Ki-67 labeling index (p < 0.001).Clinical outcomes
The correlations of clinical outcomes with various clinico-
pathological factors and EMP2 protein level as well as Ki-67
labeling index are shown in Table 3. As shown in Fig. 2,
follow-up for some patients have extended to 240 months;Table 3 Univariate log-rank survival analysis in 161 gallbladder
Parameter Patient (n) Disease
n
Gender
Male 63 18
Female 98 50
Age (y)
<70 85 30
70 76 38
Primary tumor (pT)
T1 33 7
T2 54 22
T3eT4 74 39
Stage
I 30 5
II 43 17
IIIeIV 88 46
Histological type
Papillary 17 9
Tubular 132 51
Others 12 8
Histological grade
Grade 1 79 35
Grade 2e4 82 33
Vascular invasion
Absent 105 35
Present 56 33
Perineural invasion
Absent 137 56
Present 24 12
Tumor necrosis
Absent 85 36
Present 76 32
EMP2 expression
High 79 20
Low 82 48
Ki-67 labeling index
High (50%) 66 39
Low (<50 %) 95 29
EMP2 Z epithelial membrane protein-2.
* Statistically significant.however, most patients were subjected to rapid disease
relapse. Therefore, the median follow-up duration did not
reach 240 months. Poor DSS and DFS were associated with
older patients (p Z 0.0017; p Z 0.0090), advanced pT
(pZ 0.0001; p < 0.0001) and AJCC (p < 0.0001; p < 0.0001;
Fig. 2A and B) stages, vascular invasion (p < 0.0001;
p < 0.0001), low EMP2 level (p < 0.0001; p < 0.0001; Fig. 2C
and D) and high Ki-67 labeling index (p< 0.0001; pZ 0.0002;
Fig. 2E and F). The histological type of GBC was also asso-
ciated with DSF (p Z 0.0476), but not with DSS. In multi-
variate analyses, low EMP2 protein level [p < 0.001, hazard
ratio (HR)Z 3.315; pZ 0.002, HRZ 2.224] and high Ki-67
labeling index (p < 0.001, HR Z 2.537; p Z 0.002, 1.995)
steadily remained as robust prognosticators for inferior
DSS and DFS, respectively, following age (p Z 0.001,
HR Z 2.361; p Z 0.008, HR Z 1.755) and III-IV AJCC stage
(p < 0.001, HRZ 4.950; p < 0.001, 5.464; Table 4).carcinomas patients with available follow-up information.
-specific survival Disease-free survival
p n p
0.1032 62 0.7859
33
0.0017* 47 0.0090*
48
0.0001* 9 <0.0001*
32
54
<0.0001* 7 <0.0001*
24
64
0.0875 10 0.0476*
75
10
0.3249 48 0.1640
47
<0.0001* 53 <0.0001*
42
0.2695 79 0.2911
16
0.7103 50 0.5574
45
<0.0001* 35 0.0001*
60
<0.0001* 50 0.0002*
45
Figure 2 KaplaneMeier plotting illustrates the prognostic significance of tumor stage for: (A) disease-specific survival, and
(B) disease-free survival, respectively. The predictive values of (C, D) epithelial membrane protein-2 (EMP2) and (E, F) Ki-67 are
also demonstrated. Exp. Z expression.
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In the present study, we found that loss of EMP2 immuno-
staining is one independent and potent prognosticator for
both DSS and DFS in a subset of patients with GBC, similar to
our previous study in the nasopharyngeal carcinoma.16Instead, significantly high EMP2 expression was found in
ovarian cancer through activation of caveolins/glyco-
sylphosphatidyl inositol-linked proteins,17 andwas identified
as an early predictor of endometrial cancers with unfavor-
able outcome.18 Due to non-neoplastic peritoneal, surface
tissues were complete negative for EMP2 staining; thus EMP2
Table 4 Multivariate analysis of disease-specific survival and disease-free survival.
Parameter Category Disease-specific survival Disease-free survival
HR 95% CI p HR 95% CI p
Age (y) 0.001* 0.008*
<70 1 d 1 d
70 2.361 1.414e3.941 1.755 1.156e2.663
Stage <0.001* <0.001*
I 1 d 1
II 3.155 1.701e5.848 2.717 1.629e4.525
IIIeIV 4.950 1.859e13.158 5.464 2.398e12.50
EMP2 expression <0.001* 0.002*
High 1 d 1 d
Low 3.315 1.769e6.213 2.224 1.347e3.672
Kie67 labeling index <0.001* 0.002*
Low 1 d 1 d
High 2.537 1.506e4.275 1.995 1.296e3.072
Vascular invasion 0.292 0.349
Absence 1 d 1 d
Presence 1.385 0.755e2.538 1.279 0.468e1.307
Histology type d 0.576
Papillary d d 1 d
Tubular d d 1.168 0.591e2.306
Others d d 1.287 0.513e3.227
CI Z confidence interval; EMP2 Z epithelial membrane protein-2; HR Z hazard ratio.
* Statistically significant.
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ovarian cancer.19 Moderately intensive diffuse immunohis-
tochemical staining of tumor cell cytoplasm were identified
in endometrioid adenocarcinoma, serous carcinoma, mixed
endometrioid, and clear cell carcinoma.20 However,
compared to undifferentiated ones, EMP2 is strongly
expressed in squamous metaplasia of nasopharyngeal
epithelium; loss of EMP2 expression was identified in
advanced TNM stages and confers an independent prognos-
ticator in nasopharyngeal carcinomas.16 Along with the
expression pattern of EMP2 in patients with GBC, we suggest
that EMP2 might play distinct roles in different organs
through interaction with various membrane proteins in tis-
sue- and time-specific manners.
These aspects are reflected in several studies. For
example, surface expression of the a6b1 integrin was spe-
cifically increased by EMP2 in NIH3T3 fibroblasts.21 More-
over, surface expression and trafficking of integrin a5b3
during the window of implantation, which are essential for
endometrial-blastocyst interaction in mice, were affected
by the EMP2 level and the association between EMP2 and
focal adhesion kinase.18,22,23 In mammals, 18 a and 8 b
subunits assemble into 24 different integrins, which bind
collagens, laminins, or arginineeglycineeaspartic acid-
containing proteins. Integrins are regulated by conforma-
tional changes, clustering, and trafficking and regulatory
mechanisms differ strongly between individual integrins
and between cell types. Defective integrin activation or
integrin signaling is associated with an array of pathological
conditions.24 Endocytosis and recycling are crucial in the
regulation of integrin turnover and redistribution in
adherent cells, especially during dynamic processes such as
migration and invasion.25 Therefore, EMP2 probably plays atumor suppressor role through interacting with specific
integrin(s) in epithelial cells, and thereafter, manages
regular signaling transduction in benign conditions.
A high labeling index of Ki-67 also independently por-
tends worse DSS and DFS. The expression of Ki-67 protein is
strictly associated with cell proliferation.26 A significant
inverse correlation between EMP2 protein level and Ki-67
labeling index additionally infers that EMP2 might
embrace antiproliferative activity. Indeed, during the
multistep development of human tumors, several biological
capabilities are acquired, including the sustaining prolif-
erative signaling, evading growth suppressors, resisting cell
death, enabling replicative immortality, inducing angio-
genesis, and activating invasion and metastasis.27
Regarding evading growth suppressors, one study that
applied the suppression subtractive hybridization technol-
ogy isolated mouse ortholog Emp2, which suppresses B cell
lymphoma tumorigenicity through a functional tumor sup-
pressor phenotype in vitro and in vivo.8 Likewise, the sus-
ceptibility to allogeneic cytotoxic T lymphocytes of a
mouse malignant, Emp2-deficient cell line (MV)8 has been
enhanced by retroviral overexpression of Emp2 gene.28 In
addition, constitutive overexpression of EMP2 or other
epithelial membrane proteins including EMP1, EMP3, and
PMP22, in human HEK293 epithelial cells, leading to the
development of apoptotic phenotypes, were demonstrated
by purinergic receptor P2X, ligand-gated ion channel, 7
(P2RX7)-mediated cell blebbing, annexin V binding to
plasma membrane, and cell death, through a caspase-
dependent pathway. Physically, the C-terminal domain of
P2RX7 protein associates with EMPs and mediates some
aspects of the downstream signaling following P2RX7 acti-
vation.29 All these studies support our clinical observations,
38 C.-F. Li et al.reinforcing that EMP2 might play distinct characteristics in
different cellular contexts.
In multivariate analyses, except for EMP2 and Ki-67
protein levels, both higher AJCC stage (II-IV) and age
(70 years) contribute to the increased HRs of DSS and DFS
in patients with GBC. Stage is the most important factor in
the survival, management, and prognosis of GBC patients as
well as in those with other carcinomas.4 These findings are
consistent with the result from another cohort,30 as well as
the fact that carcinogenesis is an age-dependent process.
We further identified that EMP2 protein is negative in
nontumor epithelium, and variable but positive in adenoma
of the gallbladder, but gradually lost during transformation
to adenocarcinoma. As mentioned in the literature, GBC
can arise from either a pathway involving metaplasia or
dysplasia or one in which there is a pre-existing adenoma.31
A two-step model might explain our observations, i.e.,
oncogenes initiate gallbladder adenoma formation and
those patients with upregulations of EMP2 protein present
well differentiated, less aggressive, and better outcomes.
Loss of EMP2 expression, therefore, may serve as a mo-
lecular indicator leading to neoplastic transformation as
well as poor differentiation in GBC patients. Along with
significant correlations between loss of EMP2 expression
and advanced primary tumor, vascular, and perineural in-
vasions and Ki-67 labeling index in patients with GBC, we
consequently, advocate its prospective role in preventing
GBC progression and aggressiveness. Although the exact
characteristics of the EMP2 protein in GBC development
remain to be elucidated, the potential utility of EMP2 im-
munostaining as a prognostic biomarker in GBCs is assured.
In conclusion, loss of EMP2 expression is common and
associated with adverse prognosticators and might confer
tumor aggressiveness through impeding its interaction with
specific membrane protein(s) and antiproliferative activity,
andprobably the downstream signal transductionpathway(s).References
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